Highest development stage: Phase 1 (Australia ACTRN12618001980224)

Development status: Discontinued

Gram-negative activity

Mechanism of Action/Target pathogen: Active against <i>Pseudomonas aeruginosa</i> including beta-lactamase producing strains

Reason dropped: Unspecified safety reasons (suspected hepatotoxicity)

Additional information: Synthetic compound; siderophore-cephalosporin conjugate; combination with GT-055 also shows activity against Burkholderia pseudomallei and Yersinia pestis